Medesis Pharma S.A. (ALMDP.PA)
EUR 0.34
(-2.86%)
EUR 0.34
(-2.86%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.2 Million EUR | 1.39% |
| 2022 | 1.18 Million EUR | -7.83% |
| 2021 | 1.28 Million EUR | 0.0% |
| 2020 | - EUR | -100.0% |
| 2019 | 1.78 Million EUR | 17.01% |
| 2018 | 1.52 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q2 | 2.38 Million EUR | 0.0% |
| 2023 FY | 1.2 Million EUR | 1.39% |
| 2023 Q4 | 1.2 Million EUR | -18.88% |
| 2023 Q3 | 1.47 Million EUR | -38.02% |
| 2023 Q1 | 2.38 Million EUR | 101.66% |
| 2022 Q4 | 1.18 Million EUR | 0.0% |
| 2022 Q3 | 1.18 Million EUR | 4.11% |
| 2022 FY | 1.18 Million EUR | -7.83% |
| 2022 Q2 | 1.13 Million EUR | 0.0% |
| 2022 Q1 | 1.13 Million EUR | -11.47% |
| 2021 Q3 | - EUR | 0.0% |
| 2021 Q2 | - EUR | 0.0% |
| 2021 Q1 | - EUR | 0.0% |
| 2021 Q4 | 1.28 Million EUR | 0.0% |
| 2021 FY | 1.28 Million EUR | 0.0% |
| 2020 Q2 | 2.07 Million EUR | 0.0% |
| 2020 FY | - EUR | -100.0% |
| 2020 Q4 | - EUR | 0.0% |
| 2020 Q3 | - EUR | -100.0% |
| 2019 FY | 1.78 Million EUR | 17.01% |
| 2018 FY | 1.52 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -8.992% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 97.315% |
| Adocia SA | 4.54 Million EUR | 73.568% |
| Aelis Farma SA | 2.04 Million EUR | 41.406% |
| Biophytis S.A. | 3.11 Million EUR | 61.427% |
| Advicenne S.A. | 15.89 Million EUR | 92.451% |
| genOway Société anonyme | 5.51 Million EUR | 78.258% |
| IntegraGen SA | 642.28 Thousand EUR | -86.834% |
| Neovacs S.A. | 650 Thousand EUR | -84.615% |
| NFL Biosciences SA | 39.2 Thousand EUR | -2960.99% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 72.455% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | 38.786% |
| Sensorion SA | 1.24 Million EUR | 3.297% |
| Theranexus Société Anonyme | 2.46 Million EUR | 51.234% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 69.215% |
| TheraVet SA | 1 Million EUR | -19.928% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 82.624% |
| argenx SE | 15.35 Million EUR | 92.184% |
| BioSenic S.A. | 15.57 Million EUR | 92.294% |
| Celyad Oncology SA | 902 Thousand EUR | -33.038% |
| DBV Technologies S.A. | 4.52 Million USD | 73.487% |
| Galapagos NV | 4.94 Million EUR | 75.728% |
| Genfit S.A. | 62.25 Million EUR | 98.072% |
| GeNeuro SA | 6.49 Million EUR | 81.517% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -248.837% |
| Innate Pharma S.A. | 30.6 Million EUR | 96.079% |
| Inventiva S.A. | 25.61 Million EUR | 95.315% |
| MaaT Pharma SA | 5.42 Million EUR | 77.88% |
| MedinCell S.A. | 52.8 Million EUR | 97.727% |
| Nanobiotix S.A. | 41.66 Million EUR | 97.12% |
| Onward Medical N.V. | 16.3 Million EUR | 92.641% |
| Oryzon Genomics S.A. | 3.45 Million EUR | 65.224% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 96.62% |
| Oxurion NV | 117 Thousand EUR | -925.641% |
| Pharming Group N.V. | 123.65 Million EUR | 99.03% |
| Poxel S.A. | 40.14 Million EUR | 97.011% |
| GenSight Biologics S.A. | 1.04 Million EUR | -14.504% |
| Transgene SA | 17 Thousand EUR | -6958.824% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.958% |
| Valneva SE | 132.76 Million EUR | 99.096% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |